Orthofix Medical Inc., often simply referred to as Orthofix, is a leading global medical device company that specializes in delivering innovative, minimally invasive therapeutic solutions to improve the quality of life for patients around the world. The company is publicly traded as OFIX on the NASDAQ Stock Exchange.
Orthofix's primary mission is to improve patient lives by advancing the field of orthopedic medicine with transformative, leading-edge technologies. Operating in more than 60 countries worldwide with global corporate headquarters in Lewisville, Texas, Orthofix delivers products and services that help healthcare professionals treat patients with conditions associated with the musculoskeletal system.
Orthofix's extensive product portfolio spans four strategic business units: Bone Growth Therapies, Spinal Implants, Biologics, and Orthopedics. The company is constantly pushing the boundaries of the possible, developing innovative solutions that challenge the status quo within the medical sector.
The Bone Growth Therapies division provides devices that enhance bone healing. The Spinal Implants unit offers a range of products to treat conditions related to the cervical and thoracolumbar spine. The Biologics line aims to support the body's natural healing process through applications aiding in bone fusion and tissue repair. Finally, the Orthopedics division designs, manufactures, and markets medical devices for the fixation of bone fractures and deformity correction procedures.
Orthofix prides itself on an unwavering commitment to ethics, compliance, and corporate responsibility. They dedicate themselves to improving the health of patients, collaborating with medical professionals, and contribute to communities where they operate.
The team of professionals working at Orthofix is driven by the potential of their work to make a significant, positive impact on the lives of patients around the world. With its focus on innovation and patient-centric care, Orthofix Medical Inc. has met and surpassed expectations, delivering growth and value for its shareholders and bravery and resilience for its patient community.
Despite being in a competitive medical device industry, Orthofix continues to prove itself as an industry leader, continually demonstrating its commitment to patient care and healthcare providers alike. The company's goal is not just about creating solutions but also about equipping healthcare providers with the tools they need to deliver the best care possible. With their far-reaching influence, Orthofix is helping shape the future of orthopedic medicine.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
Patrick Fisher, President of Global Limb Recon at Orthofix Medical Inc. (NASDAQ: OFIX), sold 150 shares of company common stock on September 1, 2026, at $9.39 per share. This transaction was executed under a Rule 10b5-1 trading plan established on May 29, 2026. Following the sale, Fisher maintains beneficial ownership of 51,069 shares, including previously reported restricted stock units.
Analysts have revised down the fair value and price targets for Orthofix Medical (OFIX) stock from US$15 to US$13, citing updated projections for revenue and cash generation, alongside the impact of the MDR transition. Despite the cuts, many analysts maintain a "Buy" or "Outperform" rating, indicating a continued constructive long-term outlook for the company, although specific factors like lower expected cash generation and weaker spine distributor performance contributed to the bearish adjustments.
Juniper Investment Company, a 10% owner and director of Orthofix Medical Inc. (NASDAQ:OFIX), sold 39,500 shares totaling $402,744 in two August 2026 transactions. Despite the sales and a 33% year-to-date stock decline, InvestingPro analysis suggests OFIX is undervalued, with analysts forecasting profitability for the current year. Juniper Investment Company retains significant holdings in Orthofix Medical through various funds.
Juniper Investment Company, a 10% owner of Orthofix Medical, recently purchased 39,500 common shares of Orthofix Medical between August 14-17, 2026, for approximately $402,483.1. These purchases, priced at about $10.38 and $10.01 per share, increased Juniper Multi-Strategy Fund's stake to 84,926 shares. Juniper also holds significant indirect shares through Juniper Targeted Opportunities and Juniper Targeted Opportunity Fund.